Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Garg
Amit
A
Merck & Co, Whitehouse Station, New Jersey, USA.
Maes
Andrea
A
Corr
Christy
C
Jin
Bo
B
Wadhwa
Tarun
T
Handa
Nikhil
N
Van Dyck
Kristien
K
De Lepeleire
Inge
I
Shah
Jinesh
J
Wagner
John A
JA
Krishna
Rajesh
R
D000293:Adolescent; D000328:Adult; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D065692:Cytochrome P-450 CYP3A Inhibitors; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006207:Half-Life; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D055815:Young Adult
D053480:Cholesterol Ester Transfer Proteins; D065692:Cytochrome P-450 CYP3A Inhibitors; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D023303:Oxazolidinones; D004110:Diltiazem; C530884:anacetrapib